Posted by Michael Wonder on 21 Mar 2019
NICE terminates yet another assessment of a cancer medicine
20 March 2019 - This time it is pembrolizumab (Keytruda).
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy because no evidence submission was received from Merck Sharp & Dohme. NICE will review this decision if the company decides to make a submission.
This is the 44th assessment that has been terminated by NICE. 29 of these 44 terminated assessments have been for a cancer medicine. This is the first terminated assessment of pembrolizumab.
